AHA Coding Clinic® for HCPCS - 2021 Issue 3; For Your Information

Revocation of EUA for COVID-19 monoclonal antibody treatment

Revocation of emergency use authorization (EUA) for the COVID-19 monoclonal antibody therapy bamlanivimab and deletion of HCPCS codes M0239 and Q0239 effective July 2021 The Centers for Medicare & Medicaid Services (CMS) listed new HCPCS codes M0239 and Q0239 that were established effective November 9, 2020, for bamlanivimab to track and pay appropriately for monoclonal antibodies used to treat COVID-19. The codes were added to the January 2021 I/OCE with their effective dates set to the dates they were authorized by the FDA. Effective April 16, 2021, the U.S. Food and Drug Administration revoked the emergency use...

To read the full article, sign in and subscribe to the AHA Coding Clinic® for HCPCS.


The AHA Coding Clinic for HCPCS includes:

  • The official publication for Level I HCPCS (CPT-4 codes) for hospital providers
  • Also specific Level II HCPCS codes for hospitals, physicians and other health professionals
  • Current newsletters added each quarter
  • Full Archives back to 2001
  • Fully searchable through Find-A-Code's Comprehensive Search
  • Codes mentioned in articles are linked to Code Information pages
  • Code Information page link back to related articles
  • View all the articles associated with any code, right from the code page!
Access to this feature is available in the following products:
  • AHA's Coding Clinic® - HCPCS +Archives

demo
request yours today
 subscribe
start today
 newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.